Skinbiotherapeutics PLC (LON:SBTX) Chief Executive Officer Dr Cath O’Neill caught up with DirectorsTalk for an exclusive interview to discuss the signing of an MTA with a global consumer goods company
Q1: Cath, yesterday you announced a signing of a Materials Transfer Agreement with a global consumer goods company, can you tell us what does the MTA mean?
A1: So, the Materials Transfer Agreement basically means that we, as a company, have agreed to hand over some of our technology to this other company so that they can run it through some tests and work on it themselves, the material refers to the technology. So, that’s basically what it is in a nutshell.
Q2: What does this mean then for Skinbiotherapeutics?
A2: Well, I think what it signals is that the ‘big boys’ in the consumer goods space are sitting up and taking notice of us, it’s not every day that a global giant spends its time testing the technology of a little tiny company like Skinbiotherapeutics. So, I think it’s a test to the quality of our research data, our science and the fact that they are sitting up and taking notice of us now.
